Jim Woody

Chief Executive Officer

James N. Woody, M.D., Ph.D has more than 25 years of pharmaceutical research and management expertise.

He has served as our Chief Executive Officer and as a director since the closing of the business combination in November 2020. Dr. Woody has served as the CEO of 180 since July 2020, and as a director of 180 Life Sciences since September 2020.

Dr. Woody was a founder and served as Chairman of the Board of Directors for Viracta Pharmaceuticals, a lymphoma therapeutic company (2014 to 2020). With the company undergoing a reverse merger into a public company, he resigned his Board member position and continues as a Board observer.

He has served in a variety of health and management roles including as President of Roche Bioscience, and CSO and Senior Vice President of R&D for Centocor.

At Centocor, Jim was part of the team that discovered Remicade, used to treat arthritis and which is now one of the best-selling drugs in the world.

He served as Commanding Officer and Director at the US Naval Medical Research and Development Command in Bethesda, Maryland.

In this role he was responsible for the surveillance, detection and therapy for all biologic warfare agents and infectious diseases in the First Gulf War; he was awarded the US Navy Legion of Merit for his service.

He holds an MD from Loma Linda University, and trained in pediatric immunology at Duke University and Boston Children’s Hospital (Harvard).

He further holds a PhD in Immunology from the University of London and has co-authored more than 140 publications.

Dr Jonathan Rothbard

Chief Scientific Officer

Dr Jonathan Rothbard works in the neurology department at Stanford University.

Dr Rothbard headed the Molecular Immunology Laboratory at the Imperial Cancer Research Fund in London in 1990, where he first worked with Professor Sir Marc Feldmann.

He has collaborated with Professor Lawrence Steinman since 1986, when they published the first of their 26 manuscripts together.

Dr Rothbard has been involved at a high level with start-up pharmaceuticals discovery; in 1987 he founded Amylin in San Diego and has also founded start-ups CellGate and ImmuLogic.

Amylin was focused on the discovery, development and commercialization of drugs treating diseases including diabetes and obesity.

The company was sold in 2012 to Bristol-Myers Squibb for $5.4 billion.

In addition to neurology, Dr Rothbard has also worked in the departments of chemistry and rheumatology at Stanford University.

Dr Rothbard holds a BA from Hamilton College and a PhD from Columbia University, which he followed with a fellowship at The Rockefeller University.

Prof Jagdeep Nanchahal

Head of Clinical Advisory Board

Professor Nanchahal is a surgeon scientist at the University of Oxford, focused on defining the molecular mechanisms of common diseases such as fibrosis and translating his findings through to early phase clinical trials

His surgical background has allowed him to bring a unique insight to common, yet relatively neglected diseases

Many of his findings stem from investigations in primary human tissues, rather than relying on animal models that often fail to recreate human clinical conditions

He has pioneered the treatment of fibrosis of the hand (Dupuytren’s disease), which unlike fibrosis in major human tissues can be diagnosed early and samples easily obtained to discover new pathways of importance

In 2013 his group identified TNF⍺ as a target for Dupuytren’s disease, leading to a phase 2a clinical trial to determine the effective dose and preparation of anti-TNF

Ozan Pamir

Chief Financial Officer

Ozan has played a key role in the formation of 180 Life Sciences as the CFO of two of the subsidiaries since late 2018 and oversaw the merger of 180 Therapeutics, Katexco and Cannbiorex, which now form 180 Life Sciences. He was instrumental in completing the company’s NASDAQ listing and managed majority of the funding rounds for the company.

Throughout his career, Ozan has specialized in helping companies in defining their corporate strategy, and executing corporate transactions such as M&As and IPOs. He brings a wealth of knowledge and experience to the 180 Life Sciences team as a former investment banker with in-depth capital markets expertise. Ozan was previously VP of Investment Banking at a leading Canadian independent investment bank, where he co-founded the origination department which focused on small and mid-cap financing and advisory mandates. In this role he advised private and public companies on M&A deals and was the lead banker on more than 30 financings, raising approximately $400 million.

After his investment banking career, Ozan has worked with early stage biotech companies as CFO and/or a board member. Ozan was the CFO of Enosi Life Sciences and the CFO and a board member of Unify Pharmaceuticals, both pre-clinical companies focused on autoimmune diseases.

Ozan holds an Economics and Finance degree from McGill University and is a CFA Charterholder.